Inactive Instrument

Apricus Biosciences Inc Nasdaq

US03832V1098

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets
- ^USD	-

May. 16	Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding	CI
May. 14	Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance	MT

Apricus Bioscience Inc : Apricus Biosciences and Elis Pharma Sign License Agreement for MycoVa™ in the Middle East and the Gulf

January 10, 2012 at 01:13 pm EST

MarketScreener.com By

SAN DIEGO and DUBAI, United Arab Emirates, January. 10, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") () (Nasdaq:APRI) and Elis Pharmaceuticals ("Elis") (), announced today that the two companies have entered into a licensing agreement granting Elis the exclusive rights to market MycoVa

Latest news about Apricus Biosciences Inc

Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding	May. 15	CI
Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance	May. 14	MT
Seelos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 14	CI
Seelos Therapeutics, Inc. Announces Resignation of Daniel J. O?Connor from the Board	May. 03	CI
Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors	Apr. 29	CI
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	Mar. 19	MT
Seelos Therapeutics' ALS treatment fails in mid-stage study	Mar. 19	RE
Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)	Mar. 19	CI
Seelos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Singapore Stocks Open on Monday in Red; IX Biopharma’s Stock Plunge 9% Following Contract Termination	Mar. 04	MT
IX Biopharma’s Subsidiary Issues Termination Notice for Licensing Agreement; Shares Plunge 9%	Mar. 03	MT
Seelos Therapeutics Launches Registered Direct Offering, Concurrent Private Placement	Jan. 26	MT
Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002	Jan. 22	CI
Certain Warrants of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	Jan. 12	CI
Certain Stock Options of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	Jan. 12	CI
Certain Common Stock of Seelos Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-JAN-2024.	Jan. 12	CI
Sector Update: Health Care Stocks Gain Premarket Tuesday	Dec. 19	MT
Seelos Therapeutics Files $250 Million Mixed Shelf	Dec. 19	MT
Seelos Therapeutics, Inc.(NasdaqCM:SEEL) dropped from S&P Global BMI Index	Dec. 18	CI
Seelos Therapeutics Insider Bought Shares Worth $100,223, According to a Recent SEC Filing	Dec. 01	MT
Sector Update: Health Care Stocks Mixed Late Afternoon	Nov. 29	MT
Sector Update: Health Care	Nov. 29	MT
Top Midday Decliners	Nov. 29	MT
Top Premarket Decliners	Nov. 29	MT
Seelos Therapeutics Prices Common Stock Offering	Nov. 29	MT

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The Company operates under one segment which develops pharmaceutical products. The Company's programs include SLS-002 for the potential treatment of acute suicidal ideation and behavior (ASIB) in patients with major depressive disorder (MDD) and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA). SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs). SLS-005 is used for the potential treatment of Sanfilippo Syndrome. SLS-005 is IV trehalose, a protein stabilizer that crosses the blood-brain barrier and activates autophagy and the lysosomal pathway. The Company's ongoing preclinical programs include SLS-004, SLS-006, and SLS-007.

Sector

Biotechnology & Medical Research

Calendar

2024-08-01 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+16.49%	122B
REGENERON PHARMACEUTICALS, INC.	+21.73%	115B
ARGENX SE	+22.27%	26.64B
BIONTECH SE	-21.81%	19.91B
GENMAB A/S	-16.84%	16.32B
BEIGENE, LTD.	-18.81%	15.49B
WUXI APPTEC CO., LTD.	-44.74%	15.52B
SAREPTA THERAPEUTICS, INC.	+62.72%	14.83B
NEUROCRINE BIOSCIENCES, INC.	+3.09%	13.67B

Bio Therapeutic Drugs

Apricus Biosciences Inc Nasdaq

Equities

US03832V1098

Biotechnology & Medical Research

Apricus Bioscience Inc : Apricus Biosciences and Elis Pharma Sign License Agreement for MycoVa™ in the Middle East and the Gulf

Latest news about Apricus Biosciences Inc

Chart Apricus Biosciences Inc

Company Profile

Sector Bio Therapeutic Drugs